Breast cancer known therapeutics market on Tuesday.

Side effects Is On: pharmaceutical companies compete to less toxic effective therapies for Breast Cancer fight to developThe Pharmaceutical / Biotechnology Group at Frost & Sullivan is pleased to announce 2008 Quarterly Analyst Briefing Presentation on the targeted therapies segment of U.S. Breast cancer known therapeutics market on Tuesday, February instead of 2008 at 12.00 clock CST / 13:00 ET.

As seen in our Phase III study results has onconase significant efficacy in patients shown with malignant mesothelioma, which in failed prior chemotherapy. ‘.. The paper is the result of research by staff at the Brander Cancer Research Institute and the Department of Pathology at New York Medical College and Alfacell performed. The study showed that silencing the glyceraldehyde-3 – phosphate dehydrogenase gene was prevented in human lung adenocarcinoma A549 cells by siRNA effectively by onconase. Whereas transfection of cells with GAPDH siRNA reduced expression of this protein by almost 70 %, has been exposed to the expression in the cells for 48 or 72 hours restored Onconase.###Media Contacts: Karen Richardson, and Shannon Koontz, on 336-716-4587.over Wake Forest University School Baptist Medical Center: Wake Forest Baptist is a refereed academic healthcare system, North Carolina Baptist Hospital and Wake Forest University Health Sciences that working the University School of Medicine. The system comprises 1,282 acute care, psychiatry, rehabilitation and long-term care beds and is regularly one of the most one of America’s Best Hospitals of U.S. News and World Report.